ATLANTA, Sept. 20, 2016 /PRNewswire/ -- UCB announced today the opening of its UCB Solution Accelerator – a unique environmentdesigned to drive collaboration between UCB and the Georgia Tech community to develop solutions that will positively impact the lives of those living with severe diseases. The 2,500-square foot innovation center will be located
With its North America Headquarters in Smyrna, GA, UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to treat severe diseases of the immune and central nervous system. As the first pharmaceutical company with an innovation center in Technology Square, UCB will be able to tap into Georgia Tech's state of the art machine learning and advanced analytics resources to improve patient care as well as the patient experience.
"Establishing a presence in Technology Square is a natural extension of our existing relationship with Georgia Tech," said Jeff Wren, head of UCB's Neurology Patient Value Unit. "We are thrilled to join this vibrant innovation community to learn and grow our own capabilities. We are confident that co-location and proximity to the Georgia Tech community will enable us to quickly develop quality solutions that will create real value for the patients we serve."
For the past year, UCB has collaborated with Georgia Tech's Interoperability & Integration Innovation Lab (I3L) in using predictive analytics to answer the question: how can we better fit medications to patients and positively impact patient care?
"We are delighted to welcome UCB as the first pharmaceutical company to join the growing innovation ecosystem in Tech Square," said Georgia Tech President G. P. "Bud" Peterson. "We have already begun several collaborations with the company, and look forward to future opportunities for Georgia Tech students, faculty, and staff to help develop solutions to positively impact patient care for those living with chronic, severe diseases."
UCB expects the space to be used by multiple collaborators from Georgia Tech researchers, faculty and students, to UCB interns and staff from its North America headquarters as well as from its global headquarters in Brussels Belgium.
About UCBAt UCB, we have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe immunological diseases and central nervous system disorders. With 7,500 employees in 40 countries, the company generated revenue of €3.9 billion in 2015 and invested approximately 27% of revenue in cutting-edge scientific research to meet unmet patient needs. UCB is listed on Euronext Brussels (symbol: UCB). For more information, visit www.ucb.com or follow us on Twitter at @UCB_news
For More Information:Kristie MadaraCorporate CommunicationsUCB, Inc.(770) 970-8726 (office)(770) 597-3702 (mobile) [email protected]
Laura Diamond National Media Relations Institute Communications Georgia Institute of Technology (404) 894-6016 (office) (404) 660-2927 (mobile) [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ucb-opens-solution-accelerator-at-georgia-tech-technology-square-300330211.html
SOURCE UCB, Inc.
Subscribe to our Free Newsletters!
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms ...
When a person overeats, he is unable to control his hunger pangs, while during an emotional/binge ...
Hypoplastic left heart syndrome is a rare congenital condition, which affects normal blood ...View All